Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc (VOR) is a clinical-stage biotechnology pioneer developing engineered hematopoietic stem cell (eHSC) therapies for hematological cancers. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and strategic developments related to their innovative platform.
Investors and researchers will find timely updates on key milestones including trial progress, regulatory filings, and partnership announcements. All content is curated to provide actionable insights into the company’s novel approach to protecting healthy cells during cancer treatments while enabling targeted tumor eradication.
The resource features press releases covering financial results, manufacturing advancements, and peer-reviewed research publications. Scientific updates detail progress in their eHSC platform’s applications for CAR-T therapies and antigen-targeted treatment regimens.
Bookmark this page for streamlined access to Vor Biopharma’s latest developments in cell engineering and hematological oncology research. Regularly updated to reflect new data presentations, clinical collaborations, and pipeline expansions.
Vor Bio (NASDAQ: VOR) reported Q3 2025 results and a broad clinical and corporate update on November 13, 2025. Multiple Phase 3 readouts for telitacicept showed positive efficacy and favorable safety across indications: gMG (96.2% ≥3‑point MG‑ADL response at 48 weeks), Sjögren’s disease (placebo‑adjusted ESSDAI −3.8; 71.8% vs 19.3% ≥3‑point ESSDAI at 24 weeks), SLE (67.1% vs 32.7% modified SRI‑4 at Week 52), and IgA nephropathy (55% reduction in 24h‑UPCR at 39 weeks). Corporate: raised expected gross proceeds of $115 million in Nov 2025 offering; cash and marketable securities were $170.5M as of Sept 30, 2025, projected to fund operations into Q2 2027.
Q3 financials show a net loss of $812.7M driven by a loss on warrant liabilities and total liabilities of $2.402B.
Vor Bio (Nasdaq: VOR) priced an underwritten public offering of 10,000,000 common shares at $10.00 per share, generating expected gross proceeds of $100 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about November 12, 2025. Vor Bio granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price, less underwriting discounts and commissions. All shares are being sold by Vor Bio pursuant to a shelf registration declared effective by the SEC on March 31, 2025. Final prospectus supplement will be filed with the SEC and copies will be available from the listed underwriters.
Vor Bio (Nasdaq: VOR) commenced an underwritten public offering of $100 million of common stock on November 10, 2025, and intends to grant underwriters a 30-day option to purchase up to an additional $15 million of shares at the public offering price, less underwriting discounts and commissions.
All shares are being offered by Vor Bio and the offering is subject to market and other conditions with no assurance it will be completed as proposed. J.P. Morgan, Jefferies, Citigroup and TD Cowen are joint book-running managers. The offering uses a shelf registration declared effective March 31, 2025, and will be made by prospectus supplement filed with the SEC.
Vor Bio (Nasdaq: VOR) reported that telitacicept met the primary endpoint in Stage A of a Phase 3 IgA nephropathy study in China, showing a rapid, clinically meaningful proteinuria reduction at Week 39.
Key metrics: 24h-UPCR -58.9% vs -8.8% (p<0.0001); eGFR stabilized (telitacicept -0.10 vs placebo -0.77); risk of ≥30% eGFR decline 6.3% vs 27.0%; remission rates 61% vs 19.5% for UPCR <0.8 g/g. Safety: more treatment-emergent AEs with telitacicept (89.3% vs 78.6%) but fewer serious AEs (2.5% vs 8.2%). RemeGen submitted a BLA to China regulators for IgAN.
Vor Bio (Nasdaq: VOR) will participate in two upcoming investor conferences in November–December 2025. The company will host a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 2:30 PM ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00 PM ET in Miami, FL.
A live webcast and archived replay of both fireside chats will be available on the investors section of www.vorbio.com.
Vor Bio (Nasdaq: VOR) announced the appointment of Jeremy Sokolove, M.D. as Chief Medical Officer effective Nov 3, 2025. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development.
His recent roles include Chief Medical Officer In-Residence at Roivant Sciences, Chief Medical Officer at Odyssey Therapeutics, Senior VP and Head of Clinical Pharmacology at GSK, and Head of Immunology Translational Science at AbbVie. He began his career on the faculty at Stanford and holds an MD from Boston University School of Medicine.
The company says Dr. Sokolove will drive clinical strategy and lead the global development program for Telitacicept, targeting BAFF/APRIL pathways to address autoimmune diseases.
Vor Bio (Nasdaq: VOR) announced that on October 15, 2025 its Compensation Committee granted inducement awards to 20 newly hired employees under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards comprise 113,478 stock options and 24,319 RSUs. Options have a 10-year term with an exercise price of $30.22 (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months). RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to the Inducement Plan and individual award agreements.
Vor Bio (Nasdaq: VOR) collaborator RemeGen presented 48-week open-label extension data for telitacicept in generalized myasthenia gravis on Oct 29, 2025.
Key efficacy: continuous-treatment patients had a mean -7.5 MG-ADL change and crossover patients -6.3 at week 48; continuous patients had mean -9.8 QMG change and crossover -9.3. 96.2% of continuous and 90.2% of crossover patients reached ≥3-point MG-ADL improvement; most adverse events were mild‑to‑moderate with no new safety signals.
Vor Bio (Nasdaq: VOR) will host a live webcast to present newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease.
The study was conducted by collaborator RemeGen. Vor Bio management and Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results.
Webcast: Tuesday, October 28, 2025 at 4:30 PM Eastern Time. Registration options include listen-only and listen-with-live Q&A links; a replay will be posted at https://ir.vorbio.com/events-presentations/ approximately two hours after the call and will remain available for 30 days.
Vor Bio (Nasdaq: VOR) said clinical data from Stage A of a China Phase 3 study of telitacicept in adults with IgA nephropathy (IgAN) will be a late-breaking oral presentation at ASN Kidney Week 2025 on Nov 8, 2025 at 10:45 AM CT.
Topline results reported a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks versus placebo (p<0.0001) and a favorable safety profile. RemeGen has submitted a BLA to China’s CDE/NMPA for IgAN; approval would be telitacicept’s fifth indication in China.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
